The insider sales are routine and non-informative. Monitor upcoming clinical catalysts or earnings for the next material event; this cluster provides no actionable signal.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 24 $26.71entry
- T+1 · 4mo ago +1.87%α +1.85% · $27.21
- T+5 · 4mo ago −1.95%α −2.32% · $26.19
- T+20 · 3mo ago −3.97%α −7.59% · $25.65
- T+60 · 29d ago −21.68%α −25.41% · $20.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two C-suite insiders at Mineralys Therapeutics sold shares totaling ~$211K in open-market transactions after exercising stock options. The sales are small relative to the $2.2B market cap (~0.01%) and follow a typical pattern of option exercise-and-sell for tax/vesting purposes, not a bearish signal. The cluster is non-informative given the trivial dollar amount and the liquidity-driven nature of the sales.
Key Financial Metrics
Key Facts
- Chief Commercial Officer Warren Eric exercised 7,438 options at $13.24 and immediately sold the same shares at $26.87 for ~$200K.
- Chief Medical Officer Rodman Malcom exercised 416 options at $15.44 and sold at $26.53 for ~$11K.
- Total open-market sales of ~$211K represent ~0.01% of MLYS's $2.2B market cap.
- Both sales are same-day exercise-and-sell transactions, consistent with tax withholding or diversification, not informed selling.
- No open-market purchases were made by any insider in the cluster.
Financial Impact
Total insider sales of ~$211K, immaterial relative to $2.2B market cap.
Risk Factors
- Insider sales could increase if the stock appreciates further, but current volume is trivial.
- No bearish signal from this cluster; risk is limited to general clinical-stage biotech volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MLYS-1784846394455 |
Track record
35 reports on MLYS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers